Journal Information
Vol. 96. Issue 6.
Pages 782-784 (01 November 2021)
Visits
3571
Vol. 96. Issue 6.
Pages 782-784 (01 November 2021)
Research Letter
Open Access
Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid
Visits
3571
Agoritsa Gravania,
Corresponding author
ritsagravani@gmail.com

Corresponding author.
, Panagiota Christoub, Stelios Tigasb,c, Ioannis D. Bassukasd,e
a Department of Dermatology, University Hospital of Ioannina, Greece
b Department of Endocrinology and Diabetes Centre, University Hospital of Ioannina, Ioannina, Greece
c Department of Endocrinology and Diabetes Centre, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
d Department of Dermatology, University Hospital of Ioannina, Ioannina, Greece
e Department of Skin and Venereal Diseases, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Tables (3)
Table 1. Criteria for the diagnosis of Bullous Pemphigoid (BP).
Table 2. Core demographic characteristics and disease history data of n = 45 bullous pemphigoid patients (BP) and n = 98 controls.
Table 3. Medications in patients with DPP4i associated bullous pemphigoid and in patients without BP despite DPP4i use.
Show moreShow less
Full Text
Dear Editor,

Bullous Pemphigoid (BP) is a serious cutaneous autoimmune disease with distinctly associated comorbidities such as neurological disorders, hypertension, and diabetes mellitus. Recently, the use of Dipeptidyl Peptidase-4 Inhibitors/gliptins (DPP4i) to control hyperglycemia was linked to the increasing prevalence of Type 2 Diabetes Mellitus (T2DM) among patients with newly diagnosed BP,1 demonstrating that the association of different drugs to certain comorbidities might partly account for the observed link of some comorbidities to BP. Accordingly, we asked whether medications used to treat further comorbidities might have modified the risk to develop BP in this setting. Herein, we report our findings on the association of BP with non-antidiabetic medications used at the time of BP diagnosis in a single-center cohort of elderly (≥70 years old) DPP4i-treated T2DM patients.

The BP cohort consisted of 45 T2DM patients on DPP4i with newly diagnosed BP after January 2010. BP diagnostic criteria are displayed in Table 1.1 All BP patients in this cohort were treated uniformly according to institutional guidelines with discontinuation of DPP4i and the combination of systemic corticosteroids in tapered doses and methotrexate used as corticosteroid-sparing agent. The controls were 98 elderly T2DM patients without BP treated with DPP4i for at least the last 30 months prior to enrollment matched at a ratio of 1:2 on gender, age (within 2 years), and year of diagnosis. Employing SPSS, categorical variables were compared with the χ2 test, and Mantel-Haenszel and Cox proportional hazard odds ratios (OR ± 95%Confidence Intervals, CI) were calculated between patients with and without BP at p-level <0.05. The findings are part of a retrospective study approved by the Institutional Research and Ethics Committee.

Table 1.

Criteria for the diagnosis of Bullous Pemphigoid (BP).

All 3 criteria must be fulfilled: 
(a) Relevant clinical presentation 
(b) Lesional skin biopsy consistent with BP 
(c) A result consistent with the diagnosis BP in at least one of the following routinely available laboratory examinations: direct immunofluorescence, indirect immunofluorescence, or ELISA 

The spectrum of the employed DPP4i did not differ between patients with and without BP (p = 0.06). Core demographic and medical history data of BP patients and controls are summarized in Table 2. Drug groups were included in the analysis when at least 10/143 patients were on regular treatment using medications of each group. Evaluating these groups together, a significantly higher risk of BP was found for patients on anticoagulants, proton pump inhibitors, and selective serotonin reuptake inhibitors, whereas the BP risk was significantly lower for those T2DM patients on statins (Table 3). Furthermore, the link of statin intake with a reduced BP risk was the only association that remained significant after focusing the analysis on the four drug groups above (Cox HR = 0.165; CI = 0.038–0.723; p = 0.017). The main limitation of this study is the relatively small number of participants; however, the cohorts were reasonably homogeneous with a noticeable number of BP patients included.

Table 2.

Core demographic characteristics and disease history data of n = 45 bullous pemphigoid patients (BP) and n = 98 controls.

Attribute  BP, n (%)  Control, n (%) 
Male gender  n = 19 (42.2%)  n = 41 (41.8%) 
Female gender  n = 26 (57.8%)  n = 57 (58.2%) 
Age (years): Median [Range]:  80 (70–92)  76.5 (70–90) 
DPP4a use interval (months) – Median [Range]  16 (0.3–60)  43.5 (30–125) 
Mean  19.6  53.9 
Comorbidities     
Cardiovascular  n = 40 (88.9%)  n = 88 (89.8%) 
Pulmonary  n = 6 (13.3%)  n = 7 (7.1%) 
Malignancies, excluding hematologic  n = 1 (2%)  n = 0 (0%) 
Psychiatric  n = 9 (20%)  n = 10 (10.2%) 
Neurologic  n = 7 (15.5%)  n = 6 (6.1%) 
Gastrointestinal  n = 11 (24.4%)  n = 15 (15.3%) 
Metabolic (dyslipidemia, hyperuricemia)  n = 29 (64.4%)  n = 72 (73.5%) 
Urogenital  n = 7 (15.6%)  n = 7 (7.1%) 
Hematologic diseases, including malignancies  n = 5 (11.1%)  n = 0 (0%) 
Ear Nose Throat / Eye disorders  n = 4 (8.9%)  n = 0 (0%) 
Rheumatologic  n = 2 (4.4%)  n = 4 (4.1%) 
Cutaneous  n = 3 (6.7%)  n = 0 (0%) 
Endocrine other than diabetes mellitus  n = 4 (8.7%)  n = 10 (10.2%) 
Table 3.

Medications in patients with DPP4i associated bullous pemphigoid and in patients without BP despite DPP4i use.

Medication  Cohort, n (%)ORa  CIb for OR
  BP (n = 45)  Controls (n = 98)      Lower  Upper 
Anticoagulants  24 (53.3%)  34 (34.7%)  0.026  2.300  1.104  4.793 
a1-adrenergic inhibitors  6 (13.3%)  7 (7.1%)  0.220  2.062  0.649  6.550 
ACE/AT2 inhibitorsc  36 (80%)  63 (64.3%)  0.064  2.292  0.954  5.503 
Beta-blockers  18 (40%)  33 (33.7%)  0.276  1.510  0.719  3.170 
Calcium channel blockers  14 (31.1%)  41 (41.8%)  0.165  0.581  0.270  1.252 
Loop diuretics  11 (24.4%)  21 (21.4%)  0.444  1.393  0.596  3.170 
Thiazide diuretics  20 (44.4%)  29 (29.6%)  0.065  2.009  0.958  4.214 
Potassium sparing diuretics  5 (11.1%)  5 (5.1%)  0.113  3.026  0.771  11.886 
Centrally acting antihypertensive drugs  4 (8%)  6 (6.1%)  0.522  1.538  0.411  5.785 
Statins  21 (46.7%)  67 (68.4%)  0.010  0.376  0.179  0.790 
Hypolipidemic, other  4 (8%)  8 (8.2%)  0.851  1.128  0.321  3.970 
Thyroxine  3 (6.7%)  9 (9.2%)  0.643  0.725  0.186  2.823 
Proton pump inhibitors  12 (26.7%)  8 (8.2%)  0.009  3.781  1.396  10.243 
Benzodiazepines  6 (13.3%)  4 (4.1%)  0.051  3.730  0.995  13.982 
Selective serotonin reuptake inhibitors  9 (20%)  6 (6.1%)  0.032  3.429  1.110  10.595 
a

Mantel-Haenszel Odds Ratio.

b

CI, 95% Confidence Intervals.

c

Angiotensin Converting Enzyme inhibitors & Angiotensin II receptor blockers.

Statin intake might lower the risk of developing BP in patients with T2DM treated with DPP4i by modifying certain inflammatory processes, probably via the promotion of an anti-inflammatory shift by inhibiting Th17 cells and IL-17 production.2 For example, in an animal model of allergic asthma, simvastatin modified the influx of inflammatory cells, including eosinophils and Treg, into the target tissues.3 Recently, Guo et al.4 reported a significantly increased association of the use of spironolactone with the risk of developing BP among patients taking DPP4i, even after adjustment for confounders (HR = 5.50, 95% CI = 1.25–7.51). Notably, although we did not evaluate specifically the effect of spironolactone, we could not confirm a higher BP risk for patients taking any K-sparing diuretic (Table 3). It is possible that variation of genetic factors in remote populations (like Korean vs. Greek patients), including differences in BP susceptibility and/or diverging pharmacogenomics, may explain differences in the susceptibility of the association of certain drugs to BP development.

It has been suggested that DPP4i-induced BP may become a model disease for a better understanding of basic autoimmunity principles.5 Targeting the role of co-medications in triggering BP in DPP4i-treated T2DM patients in prospective studies with sufficiently large patient samples might provide essential contributions to delineate missing links in the pathogenesis of this disease.

Financial support

None declared.

Authors' contributions

Agoritsa Gravani and Ioannis Bassukas designed the study.

Agoritsa Gravani, Panagiota Christou and Stelios Tigas collected data. All authors contributed to data analysis.

Agoritsa Gravani was responsible for the 1st draft; all authors revised critically and approved the final version of the manuscript.

Conflicts of interest

None declared.

References
[1]
A. Gravani, G. Gaitanis, T. Tsironi, S. Tigas, I.D. Bassukas.
Changing prevalence of diabetes mellitus in bullous pemphigoid: it is the dipeptidyl peptidase-4 inhibitors.
J Eur Acad Dermatol Venereol., 32 (2018), pp. e438-e439
[2]
A. Egesi, G. Sun, A. Khachemoune, R.M. Rashid.
Statins in skin: research and rediscovery, from psoriasis to sclerosis.
J Drugs Dermatol., 9 (2010), pp. 921-927
[3]
A. Jha, M.H. Ryu, O. Oo, J. Bews, C. Carlson, J. Scwartz, et al.
Prophylactic benefits of systemically delivered simvastatin treatment in a house dust mite challenged murine model of allergic asthma.
Br J Pharmacol., 175 (2018), pp. 1004-1016
[4]
J.Y. Guo, H.H. Chen, Y.C. Yang, P.Y. Wu, M.P. Chang, C.C. Chen.
The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
J Diabetes Complications., 34 (2020),
[5]
W. Nishie, K. Tasanen.
Gliptin-associated bullous pemphigoid: A valuable model of the mechanism of breakdown of immune tolerance against BP180.
J Invest Dermatol., 139 (2019), pp. 755-756

How to cite this article: Gravani A, Christou P, Tigas S, Bassukas ID. Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid. An Bras Dermatol. 2021;96:782–4.

Study conducted at the University Hospital of Ioannina, Ioannina, Greece.

Copyright © 2021. Sociedade Brasileira de Dermatologia
Idiomas
Anais Brasileiros de Dermatologia
Article options
Tools
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.